The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma (MMSPORADGEN)

Civil Hospices of Lyon

Status: Not yet enrolling

Conditions: Multiple Myeloma

Treatments: Genetic: DNA sequencing

Study type: Observational

Funder types: Other

Identifiers

NCT05331313

69HCL21_0492

Details and patient eligibility

About

There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of multiple myeloma
• availability of abnormal plasmocytes

Exclusion criteria

• none

Trial design

1,000 participants in 1 patient group

patients with a diagnosis of multiple myeloma

Description:

This study will involve a single patient group, namely patients with a diagnosis of multiple myeloma diagnosed by a bone marrow aspirate with cytological analysis of the bone marrow smear.Bone marrow samples obtained during the routine follow-up will undergo plasmocyte enrichment using immunopurification using CD138+ beads and nucleic acids will be extracted for sequencing.

Treatment:

Genetic: DNA sequencing